AMF Tjanstepension AB Cuts Holdings in Johnson & Johnson $JNJ

AMF Tjanstepension AB reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 86.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 16,002 shares of the company’s stock after selling 102,868 shares during the period. AMF Tjanstepension AB’s holdings in Johnson & Johnson were worth $2,444,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares in the last quarter. Wealth Group Ltd. bought a new position in shares of Johnson & Johnson during the 1st quarter valued at $218,000. Gateway Investment Advisers LLC raised its position in Johnson & Johnson by 8.6% in the 1st quarter. Gateway Investment Advisers LLC now owns 564,807 shares of the company’s stock worth $93,668,000 after purchasing an additional 44,614 shares during the period. Intergy Private Wealth LLC purchased a new stake in Johnson & Johnson during the first quarter valued at about $339,000. Finally, Joule Financial LLC increased its holdings in shares of Johnson & Johnson by 4.1% in the first quarter. Joule Financial LLC now owns 2,391 shares of the company’s stock worth $397,000 after buying an additional 95 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.4%

NYSE JNJ opened at $188.51 on Monday. The stock’s 50 day moving average is $176.18 and its 200 day moving average is $162.83. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $453.98 billion, a PE ratio of 20.16, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $189.78.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. UBS Group set a $198.00 price objective on Johnson & Johnson in a research note on Friday. Bank of America increased their price target on shares of Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research report on Friday. Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Morgan Stanley boosted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Finally, Citigroup lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, August 21st. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $188.88.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.